HU230679B1 - Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions - Google Patents

Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions Download PDF

Info

Publication number: HU230679B1
Authority: HU; Hungary
Prior art keywords: gin; ser; pro; mice; len
Prior art date: 1999-09-09

Application number

HU0301102A

Other languages

English (en)

Hungarian (hu)

Inventor

Birgit Oppmann

Waal Malefyt Rene De

Donna M Rennick

Robert A Kastelein

Maria T Wiekowski

Sergio A Lira

Satwant K Narula

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-09

Filing date

2000-09-08

Publication date

2017-08-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26860707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU230679(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-09-08 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2003-07-28 Publication of HUP0301102A2 publication Critical patent/HUP0301102A2/hu

2005-11-28 Publication of HUP0301102A3 publication Critical patent/HUP0301102A3/hu

2017-08-28 Publication of HU230679B1 publication Critical patent/HU230679B1/hu

Links

102000013462 Interleukin-12 Human genes 0.000 title description 8
108010065805 Interleukin-12 Proteins 0.000 title description 8
102000015696 Interleukins Human genes 0.000 title 1
108010063738 Interleukins Proteins 0.000 title 1
229940117681 interleukin-12 Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
108090000623 proteins and genes Proteins 0.000 claims description 130
210000004027 cell Anatomy 0.000 claims description 96
102000004169 proteins and genes Human genes 0.000 claims description 96
241000699670 Mus sp. Species 0.000 claims description 43
230000014509 gene expression Effects 0.000 claims description 39
230000000694 effects Effects 0.000 claims description 34
239000002253 acid Substances 0.000 claims description 31
241000282414 Homo sapiens Species 0.000 claims description 25
239000000203 mixture Substances 0.000 claims description 23
210000001519 tissue Anatomy 0.000 claims description 21
210000004556 brain Anatomy 0.000 claims description 20
230000004044 response Effects 0.000 claims description 19
241001465754 Metazoa Species 0.000 claims description 18
150000002500 ions Chemical class 0.000 claims description 17
235000011389 fruit/vegetable juice Nutrition 0.000 claims description 16
238000004519 manufacturing process Methods 0.000 claims description 16
239000000126 substance Substances 0.000 claims description 16
244000269722 Thea sinensis Species 0.000 claims description 14
230000012010 growth Effects 0.000 claims description 14
206010061218 Inflammation Diseases 0.000 claims description 13
230000015572 biosynthetic process Effects 0.000 claims description 13
230000004054 inflammatory process Effects 0.000 claims description 13
210000004369 blood Anatomy 0.000 claims description 12
239000008280 blood Substances 0.000 claims description 12
230000004048 modification Effects 0.000 claims description 12
238000012986 modification Methods 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 12
241000699666 Mus <mouse, genus> Species 0.000 claims description 11
210000004185 liver Anatomy 0.000 claims description 11
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
241000699660 Mus musculus Species 0.000 claims description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
230000009261 transgenic effect Effects 0.000 claims description 10
206010028980 Neoplasm Diseases 0.000 claims description 9
238000004458 analytical method Methods 0.000 claims description 9
239000000499 gel Substances 0.000 claims description 9
230000028993 immune response Effects 0.000 claims description 9
230000001965 increasing effect Effects 0.000 claims description 9
238000011830 transgenic mouse model Methods 0.000 claims description 9
210000001185 bone marrow Anatomy 0.000 claims description 8
210000002966 serum Anatomy 0.000 claims description 8
238000003786 synthesis reaction Methods 0.000 claims description 8
210000003462 vein Anatomy 0.000 claims description 8
108010002352 Interleukin-1 Proteins 0.000 claims description 7
230000001154 acute effect Effects 0.000 claims description 7
230000004071 biological effect Effects 0.000 claims description 7
230000001404 mediated effect Effects 0.000 claims description 7
201000010099 disease Diseases 0.000 claims description 6
210000004209 hair Anatomy 0.000 claims description 6
241000692870 Inachis io Species 0.000 claims description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 5
210000004204 blood vessel Anatomy 0.000 claims description 5
239000000835 fiber Substances 0.000 claims description 5
230000002068 genetic effect Effects 0.000 claims description 5
235000012907 honey Nutrition 0.000 claims description 5
229910052742 iron Inorganic materials 0.000 claims description 5
229910052717 sulfur Inorganic materials 0.000 claims description 5
239000011593 sulfur Substances 0.000 claims description 5
235000008753 Papaver somniferum Nutrition 0.000 claims description 4
240000001090 Papaver somniferum Species 0.000 claims description 4
244000046052 Phaseolus vulgaris Species 0.000 claims description 4
235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 4
206010037660 Pyrexia Diseases 0.000 claims description 4
230000033228 biological regulation Effects 0.000 claims description 4
230000001684 chronic effect Effects 0.000 claims description 4
208000035475 disorder Diseases 0.000 claims description 4
210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
239000011159 matrix material Substances 0.000 claims description 4
210000003205 muscle Anatomy 0.000 claims description 4
238000010186 staining Methods 0.000 claims description 4
208000024891 symptom Diseases 0.000 claims description 4
208000011580 syndromic disease Diseases 0.000 claims description 4
230000009885 systemic effect Effects 0.000 claims description 4
239000010936 titanium Substances 0.000 claims description 4
230000002792 vascular Effects 0.000 claims description 4
241000233866 Fungi Species 0.000 claims description 3
241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
230000009471 action Effects 0.000 claims description 3
244000052616 bacterial pathogen Species 0.000 claims description 3
210000000481 breast Anatomy 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
230000006378 damage Effects 0.000 claims description 3
210000000987 immune system Anatomy 0.000 claims description 3
230000001939 inductive effect Effects 0.000 claims description 3
210000000867 larynx Anatomy 0.000 claims description 3
210000003097 mucus Anatomy 0.000 claims description 3
210000005036 nerve Anatomy 0.000 claims description 3
239000003973 paint Substances 0.000 claims description 3
230000002093 peripheral effect Effects 0.000 claims description 3
239000000843 powder Substances 0.000 claims description 3
241000283153 Cetacea Species 0.000 claims description 2
206010010904 Convulsion Diseases 0.000 claims description 2
241000196324 Embryophyta Species 0.000 claims description 2
241000545744 Hirudinea Species 0.000 claims description 2
108060003951 Immunoglobulin Proteins 0.000 claims description 2
208000010668 atopic eczema Diseases 0.000 claims description 2
235000014121 butter Nutrition 0.000 claims description 2
230000004087 circulation Effects 0.000 claims description 2
238000010828 elution Methods 0.000 claims description 2
210000003743 erythrocyte Anatomy 0.000 claims description 2
102000018358 immunoglobulin Human genes 0.000 claims description 2
230000003834 intracellular effect Effects 0.000 claims description 2
210000001165 lymph node Anatomy 0.000 claims description 2
230000000813 microbial effect Effects 0.000 claims description 2
108091033319 polynucleotide Proteins 0.000 claims description 2
102000040430 polynucleotide Human genes 0.000 claims description 2
239000002157 polynucleotide Substances 0.000 claims description 2
238000012546 transfer Methods 0.000 claims description 2
241000208202 Linaceae Species 0.000 claims 7
235000004431 Linum usitatissimum Nutrition 0.000 claims 7
210000005259 peripheral blood Anatomy 0.000 claims 6
239000011886 peripheral blood Substances 0.000 claims 6
AFWBWPCXSWUCLB-WDSKDSINSA-N Pro-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H]1CCC[NH2+]1 AFWBWPCXSWUCLB-WDSKDSINSA-N 0.000 claims 4
208000007502 anemia Diseases 0.000 claims 4
108010031719 prolyl-serine Proteins 0.000 claims 4
WBAXJMCUFIXCNI-WDSKDSINSA-N Ser-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WBAXJMCUFIXCNI-WDSKDSINSA-N 0.000 claims 3
108010026333 seryl-proline Proteins 0.000 claims 3
101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 claims 2
102000013271 Hemopexin Human genes 0.000 claims 2
108010026027 Hemopexin Proteins 0.000 claims 2
HMNSRTLZAJHSIK-YUMQZZPRSA-N Pro-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 HMNSRTLZAJHSIK-YUMQZZPRSA-N 0.000 claims 2
XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 claims 2
208000005485 Thrombocytosis Diseases 0.000 claims 2
208000007536 Thrombosis Diseases 0.000 claims 2
210000001015 abdomen Anatomy 0.000 claims 2
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 2
210000001772 blood platelet Anatomy 0.000 claims 2
208000037824 growth disorder Diseases 0.000 claims 2
108010004914 prolylarginine Proteins 0.000 claims 2
230000036435 stunted growth Effects 0.000 claims 2
206010048998 Acute phase reaction Diseases 0.000 claims 1
102000011767 Acute-Phase Proteins Human genes 0.000 claims 1
108010062271 Acute-Phase Proteins Proteins 0.000 claims 1
IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 claims 1
SONUFGRSSMFHFN-IMJSIDKUSA-N Asn-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O SONUFGRSSMFHFN-IMJSIDKUSA-N 0.000 claims 1
DWBZEJHQQIURML-IMJSIDKUSA-N Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O DWBZEJHQQIURML-IMJSIDKUSA-N 0.000 claims 1
102000004506 Blood Proteins Human genes 0.000 claims 1
108010017384 Blood Proteins Proteins 0.000 claims 1
101100385576 Caenorhabditis elegans ctg-1 gene Proteins 0.000 claims 1
241000272161 Charadriiformes Species 0.000 claims 1
SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 claims 1
241000278325 Daphne gnidium Species 0.000 claims 1
201000004624 Dermatitis Diseases 0.000 claims 1
241000282326 Felis catus Species 0.000 claims 1
235000016623 Fragaria vesca Nutrition 0.000 claims 1
240000009088 Fragaria x ananassa Species 0.000 claims 1
235000011363 Fragaria x ananassa Nutrition 0.000 claims 1
241001123946 Gaga Species 0.000 claims 1
VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 claims 1
102000014702 Haptoglobin Human genes 0.000 claims 1
108050005077 Haptoglobin Proteins 0.000 claims 1
241000160777 Hipparchia semele Species 0.000 claims 1
101000798320 Homo sapiens Bcl-2 homologous antagonist/killer Proteins 0.000 claims 1
241000884920 Imaia Species 0.000 claims 1
240000002329 Inga feuillei Species 0.000 claims 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
206010022971 Iron Deficiencies Diseases 0.000 claims 1
208000015710 Iron-Deficiency Anemia Diseases 0.000 claims 1
PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims 1
108010079364 N-glycylalanine Proteins 0.000 claims 1
FSXRLASFHBWESK-HOTGVXAUSA-N Phe-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 FSXRLASFHBWESK-HOTGVXAUSA-N 0.000 claims 1
RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 claims 1
UEKYKRQIAQHOOZ-KBPBESRZSA-N Pro-Trp Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)[O-])C(=O)[C@@H]1CCC[NH2+]1 UEKYKRQIAQHOOZ-KBPBESRZSA-N 0.000 claims 1
208000034189 Sclerosis Diseases 0.000 claims 1
RZEQTVHJZCIUBT-WDSKDSINSA-N Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N RZEQTVHJZCIUBT-WDSKDSINSA-N 0.000 claims 1
PJIQEIFXZPCWOJ-FXQIFTODSA-N Ser-Pro-Asp Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O PJIQEIFXZPCWOJ-FXQIFTODSA-N 0.000 claims 1
CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 claims 1
101710151211 Seroin Proteins 0.000 claims 1
244000297179 Syringa vulgaris Species 0.000 claims 1
235000004338 Syringa vulgaris Nutrition 0.000 claims 1
101150023247 Tefm gene Proteins 0.000 claims 1
241000897276 Termes Species 0.000 claims 1
YKRQRPFODDJQTC-CSMHCCOUSA-N Thr-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN YKRQRPFODDJQTC-CSMHCCOUSA-N 0.000 claims 1
RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 claims 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 1
YBRHKUNWEYBZGT-WLTAIBSBSA-N Trp-Thr Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(O)=O)=CNC2=C1 YBRHKUNWEYBZGT-WLTAIBSBSA-N 0.000 claims 1
DAJVWAYAPWDUTO-UHFFFAOYSA-N [2-(hydroxymethyl)-3-phosphonooxy-5-(3-tetradecanoyloxytetradecanoylamino)oxan-4-yl] tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(CCCCCCCCCCC)CC(=O)NC1COC(CO)C(OP(O)(O)=O)C1OC(=O)CCCCCCCCCCCCC DAJVWAYAPWDUTO-UHFFFAOYSA-N 0.000 claims 1
238000001467 acupuncture Methods 0.000 claims 1
230000004658 acute-phase response Effects 0.000 claims 1
239000011717 all-trans-retinol Substances 0.000 claims 1
235000019169 all-trans-retinol Nutrition 0.000 claims 1
WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 claims 1
230000033115 angiogenesis Effects 0.000 claims 1
235000013405 beer Nutrition 0.000 claims 1
230000017531 blood circulation Effects 0.000 claims 1
210000001638 cerebellum Anatomy 0.000 claims 1
230000036461 convulsion Effects 0.000 claims 1
230000001054 cortical effect Effects 0.000 claims 1
230000002950 deficient Effects 0.000 claims 1
BQYJATMQXGBDHF-UHFFFAOYSA-N difenoconazole Chemical compound O1C(C)COC1(C=1C(=CC(OC=2C=CC(Cl)=CC=2)=CC=1)Cl)CN1N=CN=C1 BQYJATMQXGBDHF-UHFFFAOYSA-N 0.000 claims 1
FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 claims 1
230000000925 erythroid effect Effects 0.000 claims 1
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 claims 1
230000003179 granulation Effects 0.000 claims 1
238000005469 granulation Methods 0.000 claims 1
230000036541 health Effects 0.000 claims 1
241000411851 herbal medicine Species 0.000 claims 1
230000002363 herbicidal effect Effects 0.000 claims 1
230000028709 inflammatory response Effects 0.000 claims 1
230000005923 long-lasting effect Effects 0.000 claims 1
239000003120 macrolide antibiotic agent Substances 0.000 claims 1
230000007246 mechanism Effects 0.000 claims 1
238000011580 nude mouse model Methods 0.000 claims 1
230000003534 oscillatory effect Effects 0.000 claims 1
230000002018 overexpression Effects 0.000 claims 1
230000000770 proinflammatory effect Effects 0.000 claims 1
108010077112 prolyl-proline Proteins 0.000 claims 1
238000001243 protein synthesis Methods 0.000 claims 1
230000037390 scarring Effects 0.000 claims 1
210000000952 spleen Anatomy 0.000 claims 1
210000002784 stomach Anatomy 0.000 claims 1
229910052719 titanium Inorganic materials 0.000 claims 1
230000002103 transcriptional effect Effects 0.000 claims 1
230000001052 transient effect Effects 0.000 claims 1
230000014616 translation Effects 0.000 claims 1
238000002054 transplantation Methods 0.000 claims 1
230000000472 traumatic effect Effects 0.000 claims 1
210000003708 urethra Anatomy 0.000 claims 1
238000000034 method Methods 0.000 description 68
108090000765 processed proteins & peptides Proteins 0.000 description 49
108020003175 receptors Proteins 0.000 description 48
102000005962 receptors Human genes 0.000 description 48
239000000427 antigen Substances 0.000 description 41
108091007433 antigens Proteins 0.000 description 41
102000036639 antigens Human genes 0.000 description 41
230000027455 binding Effects 0.000 description 41
102000004196 processed proteins & peptides Human genes 0.000 description 37
239000012634 fragment Substances 0.000 description 34
229920001184 polypeptide Polymers 0.000 description 33
150000001413 amino acids Chemical class 0.000 description 28
239000003153 chemical reaction reagent Substances 0.000 description 28
230000004927 fusion Effects 0.000 description 22
241000288906 Primates Species 0.000 description 21
238000012360 testing method Methods 0.000 description 20
241000894007 species Species 0.000 description 18
150000007523 nucleic acids Chemical class 0.000 description 17
239000005557 antagonist Substances 0.000 description 16
241000124008 Mammalia Species 0.000 description 15
108020004707 nucleic acids Proteins 0.000 description 14
102000039446 nucleic acids Human genes 0.000 description 14
239000003814 drug Substances 0.000 description 13
108020001507 fusion proteins Proteins 0.000 description 13
239000000463 material Substances 0.000 description 13
241000283984 Rodentia Species 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 12
102000037865 fusion proteins Human genes 0.000 description 12
239000000047 product Substances 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
230000001413 cellular effect Effects 0.000 description 11
102000004127 Cytokines Human genes 0.000 description 10
108090000695 Cytokines Proteins 0.000 description 10
239000000556 agonist Substances 0.000 description 10
229940079593 drug Drugs 0.000 description 10
239000013598 vector Substances 0.000 description 10
230000008569 process Effects 0.000 description 9
239000000523 sample Substances 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
238000011282 treatment Methods 0.000 description 9
230000002159 abnormal effect Effects 0.000 description 8
238000003745 diagnosis Methods 0.000 description 8
239000011435 rock Substances 0.000 description 8
230000011664 signaling Effects 0.000 description 8
239000007787 solid Substances 0.000 description 8
239000004575 stone Substances 0.000 description 8
239000011230 binding agent Substances 0.000 description 7
235000013351 cheese Nutrition 0.000 description 7
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
230000006870 function Effects 0.000 description 7
238000002955 isolation Methods 0.000 description 7
239000002773 nucleotide Substances 0.000 description 7
125000003729 nucleotide group Chemical group 0.000 description 7
230000035479 physiological effects, processes and functions Effects 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
210000001744 T-lymphocyte Anatomy 0.000 description 6
239000000969 carrier Substances 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
230000000295 complement effect Effects 0.000 description 6
238000009472 formulation Methods 0.000 description 6
235000003642 hunger Nutrition 0.000 description 6
239000012071 phase Substances 0.000 description 6
230000035755 proliferation Effects 0.000 description 6
230000035945 sensitivity Effects 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
239000002023 wood Substances 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
240000002129 Malva sylvestris Species 0.000 description 5
235000006770 Malva sylvestris Nutrition 0.000 description 5
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 5
240000004808 Saccharomyces cerevisiae Species 0.000 description 5
230000000890 antigenic effect Effects 0.000 description 5
238000003556 assay Methods 0.000 description 5
239000011324 bead Substances 0.000 description 5
230000008859 change Effects 0.000 description 5
238000004140 cleaning Methods 0.000 description 5
239000002131 composite material Substances 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
238000001514 detection method Methods 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
238000003780 insertion Methods 0.000 description 5
230000037431 insertion Effects 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
230000035772 mutation Effects 0.000 description 5
-1 salt ethers Chemical class 0.000 description 5
241000271566 Aves Species 0.000 description 4
206010010071 Coma Diseases 0.000 description 4
241000283086 Equidae Species 0.000 description 4
244000182067 Fraxinus ornus Species 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
230000004913 activation Effects 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000004891 communication Methods 0.000 description 4
230000001934 delay Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
210000004907 gland Anatomy 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
238000003018 immunoassay Methods 0.000 description 4
230000004968 inflammatory condition Effects 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
210000001331 nose Anatomy 0.000 description 4
230000037361 pathway Effects 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
238000012552 review Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
241000251468 Actinopterygii Species 0.000 description 3
235000000832 Ayote Nutrition 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
235000009854 Cucurbita moschata Nutrition 0.000 description 3
235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
235000002917 Fraxinus ornus Nutrition 0.000 description 3
241000282412 Homo Species 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
230000010799 Receptor Interactions Effects 0.000 description 3
108700019146 Transgenes Proteins 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
230000003444 anaesthetic effect Effects 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
210000000941 bile Anatomy 0.000 description 3
230000008827 biological function Effects 0.000 description 3
235000015218 chewing gum Nutrition 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
235000019788 craving Nutrition 0.000 description 3
238000007877 drug screening Methods 0.000 description 3
235000013399 edible fruits Nutrition 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
235000019634 flavors Nutrition 0.000 description 3
235000013305 food Nutrition 0.000 description 3
210000003128 head Anatomy 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
230000002147 killing effect Effects 0.000 description 3
210000003127 knee Anatomy 0.000 description 3
239000002609 medium Substances 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
235000013336 milk Nutrition 0.000 description 3
239000008267 milk Substances 0.000 description 3
210000004080 milk Anatomy 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
230000000750 progressive effect Effects 0.000 description 3
235000015136 pumpkin Nutrition 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
231100000241 scar Toxicity 0.000 description 3
230000007017 scission Effects 0.000 description 3
238000012216 screening Methods 0.000 description 3
230000028327 secretion Effects 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
230000001629 suppression Effects 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
238000005406 washing Methods 0.000 description 3
241000238876 Acari Species 0.000 description 2
102000007469 Actins Human genes 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
240000001980 Cucurbita pepo Species 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
206010015535 Euphoric mood Diseases 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
241000976924 Inca Species 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
241001026509 Kata Species 0.000 description 2
241001435619 Lile Species 0.000 description 2
241001529936 Murinae Species 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
208000001132 Osteoporosis Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
208000025747 Rheumatic disease Diseases 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
235000008429 bread Nutrition 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
229940112822 chewing gum Drugs 0.000 description 2
235000013330 chicken meat Nutrition 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
235000009508 confectionery Nutrition 0.000 description 2
239000000470 constituent Substances 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
239000010949 copper Substances 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
210000004443 dendritic cell Anatomy 0.000 description 2
238000013461 design Methods 0.000 description 2
239000003599 detergent Substances 0.000 description 2
239000000428 dust Substances 0.000 description 2
230000004064 dysfunction Effects 0.000 description 2
239000003792 electrolyte Substances 0.000 description 2
230000002743 euphoric effect Effects 0.000 description 2
238000001400 expression cloning Methods 0.000 description 2
239000006260 foam Substances 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
230000002267 hypothalamic effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000009940 knitting Methods 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
230000003902 lesion Effects 0.000 description 2
239000003446 ligand Substances 0.000 description 2
238000005461 lubrication Methods 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
235000015090 marinades Nutrition 0.000 description 2
239000003550 marker Substances 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
230000003387 muscular Effects 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
229910052759 nickel Inorganic materials 0.000 description 2
238000010899 nucleation Methods 0.000 description 2
239000002674 ointment Substances 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
239000008188 pellet Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
150000003905 phosphatidylinositols Chemical class 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000011002 quantification Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
230000001953 sensory effect Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000010703 silicon Substances 0.000 description 2
239000002002 slurry Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000012916 structural analysis Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
210000000115 thoracic cavity Anatomy 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
238000004018 waxing Methods 0.000 description 2
GAKUNXBDVGLOFS-DUZKARGPSA-N (1-acetyloxy-3-hexadecanoyloxypropan-2-yl) (9z,12z)-octadeca-9,12-dienoate Chemical group CCCCCCCCCCCCCCCC(=O)OCC(COC(C)=O)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC GAKUNXBDVGLOFS-DUZKARGPSA-N 0.000 description 1
XPVIQPQOGTVMSU-UHFFFAOYSA-N (4-acetamidophenyl)arsenic Chemical compound CC(=O)NC1=CC=C([As])C=C1 XPVIQPQOGTVMSU-UHFFFAOYSA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
ARKDNMZXRXKLOV-UHFFFAOYSA-N 2-(2-methylpropylamino)ethyl 4-aminobenzoate;hydrochloride Chemical compound Cl.CC(C)CNCCOC(=O)C1=CC=C(N)C=C1 ARKDNMZXRXKLOV-UHFFFAOYSA-N 0.000 description 1
241001290610 Abildgaardia Species 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
235000009434 Actinidia chinensis Nutrition 0.000 description 1
244000298697 Actinidia deliciosa Species 0.000 description 1
235000009436 Actinidia deliciosa Nutrition 0.000 description 1
ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
RUQBGIMJQUWXPP-CYDGBPFRSA-N Ala-Leu-Ala-Pro Chemical group C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O RUQBGIMJQUWXPP-CYDGBPFRSA-N 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
241001093575 Alma Species 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
241000272814 Anser sp. Species 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
101150075033 Aopep gene Proteins 0.000 description 1
241001124076 Aphididae Species 0.000 description 1
241001061225 Arcos Species 0.000 description 1
235000011330 Armoracia rusticana Nutrition 0.000 description 1
240000003291 Armoracia rusticana Species 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
SPIWINZXMDJUPE-UHFFFAOYSA-N Atanine Natural products C1=CC=C2C(OC)=C(CC=C(C)C)C(O)=NC2=C1 SPIWINZXMDJUPE-UHFFFAOYSA-N 0.000 description 1
206010003658 Atrial Fibrillation Diseases 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
206010048909 Boredom Diseases 0.000 description 1
241000283725 Bos Species 0.000 description 1
101100494773 Caenorhabditis elegans ctl-2 gene Proteins 0.000 description 1
101100228200 Caenorhabditis elegans gly-5 gene Proteins 0.000 description 1
101100504103 Caenorhabditis elegans gpb-2 gene Proteins 0.000 description 1
241000282421 Canidae Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
235000002566 Capsicum Nutrition 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
241000252254 Catostomidae Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
JFPVXVDWJQMJEE-QMTHXVAHSA-N Cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)C(=NOC)C1=CC=CO1 JFPVXVDWJQMJEE-QMTHXVAHSA-N 0.000 description 1
208000035484 Cellulite Diseases 0.000 description 1
241000282994 Cervidae Species 0.000 description 1
206010068051 Chimerism Diseases 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
235000006481 Colocasia esculenta Nutrition 0.000 description 1
244000205754 Colocasia esculenta Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
241000938605 Crocodylia Species 0.000 description 1
235000004035 Cryptotaenia japonica Nutrition 0.000 description 1
241000219122 Cucurbita Species 0.000 description 1
241000219130 Cucurbita pepo subsp. pepo Species 0.000 description 1
235000003954 Cucurbita pepo var melopepo Nutrition 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
241000238557 Decapoda Species 0.000 description 1
208000006558 Dental Calculus Diseases 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
PQUCIEFHOVEZAU-UHFFFAOYSA-N Diammonium sulfite Chemical compound [NH4+].[NH4+].[O-]S([O-])=O PQUCIEFHOVEZAU-UHFFFAOYSA-N 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
241000255925 Diptera Species 0.000 description 1
206010013911 Dysgeusia Diseases 0.000 description 1
241000500884 Ephemera Species 0.000 description 1
241000283070 Equus zebra Species 0.000 description 1
101100112369 Fasciola hepatica Cat-1 gene Proteins 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
206010017577 Gait disturbance Diseases 0.000 description 1
241000237858 Gastropoda Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
241001093366 Gonista Species 0.000 description 1
206010018612 Gonorrhoea Diseases 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
229920004449 Halon® Polymers 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
241000282313 Hyaenidae Species 0.000 description 1
QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
101150017040 I gene Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
208000025814 Inflammatory myopathy with abundant macrophages Diseases 0.000 description 1
102000004560 Interleukin-12 Receptors Human genes 0.000 description 1
108010017515 Interleukin-12 Receptors Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
241000726306 Irus Species 0.000 description 1
241001501267 Iseia Species 0.000 description 1
241000567769 Isurus oxyrinchus Species 0.000 description 1
241000581650 Ivesia Species 0.000 description 1
240000007049 Juglans regia Species 0.000 description 1
235000009496 Juglans regia Nutrition 0.000 description 1
125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000282553 Macaca Species 0.000 description 1
241000020990 Macrodes Species 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
241000940612 Medina Species 0.000 description 1
206010027783 Moaning Diseases 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
241001504654 Mustela nivalis Species 0.000 description 1
102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 1
241000772415 Neovison vison Species 0.000 description 1
101100005271 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-1 gene Proteins 0.000 description 1
101100230509 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) hat-1 gene Proteins 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
241000819999 Nymphes Species 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
240000008881 Oenanthe javanica Species 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241001327682 Oncorhynchus mykiss irideus Species 0.000 description 1
241000237502 Ostreidae Species 0.000 description 1
241000346285 Ostrinia furnacalis Species 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
235000006484 Paeonia officinalis Nutrition 0.000 description 1
244000170916 Paeonia officinalis Species 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010033425 Pain in extremity Diseases 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
206010049752 Peau d'orange Diseases 0.000 description 1
239000006002 Pepper Substances 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
235000014676 Phragmites communis Nutrition 0.000 description 1
235000016761 Piper aduncum Nutrition 0.000 description 1
240000003889 Piper guineense Species 0.000 description 1
235000017804 Piper guineense Nutrition 0.000 description 1
235000008184 Piper nigrum Nutrition 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
208000037062 Polyps Diseases 0.000 description 1
241000204357 Porites Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
101710081227 Protein cortex Proteins 0.000 description 1
241001155165 Protermes Species 0.000 description 1
235000005805 Prunus cerasus Nutrition 0.000 description 1
240000002878 Prunus cerasus Species 0.000 description 1
235000009226 Prunus puddum Nutrition 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010037888 Rash pustular Diseases 0.000 description 1
241000246123 Retama raetam Species 0.000 description 1
244000299790 Rheum rhabarbarum Species 0.000 description 1
235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
241000220317 Rosa Species 0.000 description 1
206010039509 Scab Diseases 0.000 description 1
208000008765 Sciatica Diseases 0.000 description 1
241000555745 Sciuridae Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
GRXKLBBBQUKJJZ-UHFFFAOYSA-N Soman Chemical compound CC(C)(C)C(C)OP(C)(F)=O GRXKLBBBQUKJJZ-UHFFFAOYSA-N 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
101100388071 Thermococcus sp. (strain GE8) pol gene Proteins 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical group O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
101150045848 Tmbim6 gene Proteins 0.000 description 1
241000383675 Trama Species 0.000 description 1
102000007641 Trefoil Factors Human genes 0.000 description 1
235000015724 Trifolium pratense Nutrition 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
244000098338 Triticum aestivum Species 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
241000863480 Vinca Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
241000282485 Vulpes vulpes Species 0.000 description 1
101100070529 Xenopus laevis hesx1-b gene Proteins 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
229910021536 Zeolite Inorganic materials 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
206010000496 acne Diseases 0.000 description 1
239000013543 active substance Substances 0.000 description 1
238000011374 additional therapy Methods 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
230000008484 agonism Effects 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000007815 allergy Effects 0.000 description 1
108090000637 alpha-Amylases Proteins 0.000 description 1
102000004139 alpha-Amylases Human genes 0.000 description 1
229940024171 alpha-amylase Drugs 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000003109 amnesic effect Effects 0.000 description 1
229920013640 amorphous poly alpha olefin Polymers 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000002519 antifouling agent Substances 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
229940125716 antipyretic agent Drugs 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
238000010009 beating Methods 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
235000015895 biscuits Nutrition 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
239000011449 brick Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
JLQUFIHWVLZVTJ-UHFFFAOYSA-N carbosulfan Chemical compound CCCCN(CCCC)SN(C)C(=O)OC1=CC=CC2=C1OC(C)(C)C2 JLQUFIHWVLZVTJ-UHFFFAOYSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000036232 cellulite Effects 0.000 description 1
206010008129 cerebral palsy Diseases 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
235000015111 chews Nutrition 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
230000009194 climbing Effects 0.000 description 1
230000035602 clotting Effects 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000000571 coke Substances 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
239000004567 concrete Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000010411 cooking Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000035622 drinking Effects 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
208000010515 dystocia Diseases 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
DNORZUSMZSZZKU-UHFFFAOYSA-N ethyl 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate Chemical compound C=1C=C(Cl)C=CC=1CCCCCC1(C(=O)OCC)CO1 DNORZUSMZSZZKU-UHFFFAOYSA-N 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
206010016531 fetishism Diseases 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
244000144992 flock Species 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
150000002240 furans Chemical class 0.000 description 1
239000010437 gem Substances 0.000 description 1
229910001751 gemstone Inorganic materials 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000000762 glandular Effects 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
208000001786 gonorrhea Diseases 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000004519 grease Substances 0.000 description 1
235000021384 green leafy vegetables Nutrition 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
230000000652 homosexual effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
210000002758 humerus Anatomy 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
235000015243 ice cream Nutrition 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000030214 innervation Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
229960002479 isosorbide Drugs 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008141 laxative Substances 0.000 description 1
229940125722 laxative agent Drugs 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
239000004571 lime Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
241000238565 lobster Species 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000013011 mating Effects 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000003607 modifier Substances 0.000 description 1
230000004879 molecular function Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
238000010417 needlework Methods 0.000 description 1
229910000480 nickel oxide Inorganic materials 0.000 description 1
230000006911 nucleation Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000005457 optimization Methods 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
GNRSAWUEBMWBQH-UHFFFAOYSA-N oxonickel Chemical class [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 description 1
235000020636 oyster Nutrition 0.000 description 1
238000010422 painting Methods 0.000 description 1
230000001769 paralizing effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
210000003899 penis Anatomy 0.000 description 1
230000006071 peptidylation Effects 0.000 description 1
230000008823 permeabilization Effects 0.000 description 1
239000012466 permeate Substances 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
230000007096 poisonous effect Effects 0.000 description 1
230000010287 polarization Effects 0.000 description 1
229920013639 polyalphaolefin Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
244000062645 predators Species 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000037452 priming Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
239000001294 propane Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000002331 protein detection Methods 0.000 description 1
238000000164 protein isolation Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
208000029561 pustule Diseases 0.000 description 1
239000010453 quartz Substances 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000000384 rearing effect Effects 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
238000009877 rendering Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000000552 rheumatic effect Effects 0.000 description 1
230000001020 rhythmical effect Effects 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
230000009919 sequestration Effects 0.000 description 1
102000035025 signaling receptors Human genes 0.000 description 1
108091005475 signaling receptors Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
238000004088 simulation Methods 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
SLZHLQUFNFXTHB-UHFFFAOYSA-M sodium;5-butan-2-yl-5-ethyl-2-sulfanylidenepyrimidin-3-ide-4,6-dione Chemical compound [Na+].CCC(C)C1(CC)C([O-])=NC(=S)NC1=O SLZHLQUFNFXTHB-UHFFFAOYSA-M 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000037351 starvation Effects 0.000 description 1
230000003068 static effect Effects 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000003463 sulfur Chemical class 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
JDFUJAMTCCQARF-UHFFFAOYSA-N tatb Chemical compound NC1=C([N+]([O-])=O)C(N)=C([N+]([O-])=O)C(N)=C1[N+]([O-])=O JDFUJAMTCCQARF-UHFFFAOYSA-N 0.000 description 1
230000029305 taxis Effects 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
230000035922 thirst Effects 0.000 description 1
JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 1
229960002312 tolazoline Drugs 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
239000002435 venom Substances 0.000 description 1
210000001048 venom Anatomy 0.000 description 1
231100000611 venom Toxicity 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
235000020234 walnut Nutrition 0.000 description 1
238000009941 weaving Methods 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000002087 whitening effect Effects 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
239000010457 zeolite Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Zoology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Transplantation (AREA)
Virology (AREA)
Dermatology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)

HU0301102A 1999-09-09 2000-09-08 Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions HU230679B1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US39309099A	1999-09-09	1999-09-09
US16461699P	1999-11-10	1999-11-10
PCT/US2000/024686 WO2001018051A2 (en)	1999-09-09	2000-09-08	Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions

Publications (3)

Publication Number	Publication Date
HUP0301102A2 HUP0301102A2 (hu)	2003-07-28
HUP0301102A3 HUP0301102A3 (en)	2005-11-28
HU230679B1 true HU230679B1 (en)	2017-08-28

Family

ID=26860707

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0301102A HU230679B1 (en)	1999-09-09	2000-09-08	Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions

Country Status (15)

Country	Link
EP (1)	EP1210434B2 (2)
JP (6)	JP4505166B2 (2)
KR (1)	KR100894359B1 (2)
CN (1)	CN100529076C (2)
AR (1)	AR035560A1 (2)
AT (1)	ATE389019T1 (2)
AU (2)	AU780163B2 (2)
CA (1)	CA2388562C (2)
DE (1)	DE60038304T3 (2)
ES (1)	ES2300276T5 (2)
HK (1)	HK1044170B (2)
HU (1)	HU230679B1 (2)
IL (1)	IL148300A0 (2)
MX (1)	MXPA02002684A (2)
WO (1)	WO2001018051A2 (2)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2007202362B2 (en) *	1999-09-03	2011-06-23	Merck Sharp & Dohme Corp.	Mammalian receptor proteins; related reagents and methods
US7422743B2 (en)	2000-05-10	2008-09-09	Schering Corporation	Mammalian receptor protein DCRS5;methods of treatment
US6756481B2 (en)	2000-05-10	2004-06-29	Schering Corporation	IL-23 receptor binding compositions
WO2004042009A2 (en)	2002-10-30	2004-05-21	Genentech, Inc.	Inhibition of il-17 production
WO2004058178A2 (en)	2002-12-23	2004-07-15	Schering Corporation	Uses of mammalian cytokine; related reagents
US7282204B2 (en)	2003-03-10	2007-10-16	Schering Corporation	Uses of IL-23 agonists and antagonists; related reagents
CN101052726A (zh)	2003-05-09	2007-10-10	森托科尔公司	IL－23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途
EP1522858A1 (en) *	2003-10-10	2005-04-13	Jean-Christophe Roegel	Methods for selecting compounds using antibodies with activity as agonist, antagonist or allosteric modulators
WO2005108425A1 (en) *	2004-05-10	2005-11-17	Cytos Biotechnology Ag	Il-23 p19 antigen array and uses thereof
AR051444A1 (es)	2004-09-24	2007-01-17	Centocor Inc	Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US7820168B2 (en)	2004-12-20	2010-10-26	Schering Corporation	Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17
SI2452694T1 (sl)	2005-06-30	2019-05-31	Janssen Biotech, Inc.	Protitelesa proti-IL-23, sestavki in postopki uporabe
DE602006015830D1 (de)	2005-08-25	2010-09-09	Lilly Co Eli	Anti-il-23-antikörper
PT1931710T (pt)	2005-08-31	2017-03-28	Merck Sharp & Dohme	Anticorpos anti-il-23 manipulados
HUE034269T2 (en)	2005-12-29	2018-02-28	Janssen Biotech Inc	Human anti-IL-23 antibodies, preparations, methods and applications
PL1966238T3 (pl)	2005-12-30	2012-09-28	Merck Patent Gmbh	Warianty interleukiny-12p40 o polepszonej stabilności
US7910703B2 (en)	2006-03-10	2011-03-22	Zymogenetics, Inc.	Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US7790862B2 (en)	2006-06-13	2010-09-07	Zymogenetics, Inc.	IL-17 and IL-23 antagonists and methods of using the same
TWI426918B (zh)	2007-02-12	2014-02-21	Merck Sharp & Dohme	Ｉｌ-２３拮抗劑於治療感染之用途
JP2010518858A (ja)	2007-02-23	2010-06-03	シェーリングコーポレイション	操作された抗−ｉｌ−２３ｐ１９抗体
ES2708988T3 (es)	2007-02-23	2019-04-12	Merck Sharp & Dohme	Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
NZ579251A (en)	2007-02-28	2012-06-29	Schering Corp	Engineered anti-il-23r antibodies
CA2679400A1 (en)	2007-02-28	2008-09-04	Schering Corporation	Combination therapy for treatment of immune disorders
EP2650311A3 (en)	2007-11-27	2014-06-04	Ablynx N.V.	Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
JPWO2009133863A1 (ja) *	2008-04-28	2011-09-01	国立大学法人浜松医科大学	Ｅｐ１アゴニストを含有してなる免疫増強剤
JO3244B1 (ar)	2009-10-26	2018-03-08	Amgen Inc	بروتينات ربط مستضادات il – 23 البشرية
MX2019000046A (es)	2010-11-04	2023-10-05	Boehringer Ingelheim Int	Anticuerpos anti-il-23.
CN102462837B (zh)	2010-11-19	2016-08-03	生物林格斯Ip有限公司	抗炎组合物
EP2850093B1 (en)	2012-01-27	2019-01-09	The Board of Trustees of the Leland Stanford Junior University	Therapeutic il-13 polypeptides
PL3326649T3 (pl)	2012-05-03	2022-04-25	Boehringer Ingelheim International Gmbh	Przeciwciała anty-il-23p19
ES2729603T3 (es)	2012-06-27	2019-11-05	Merck Sharp & Dohme	Anticuerpos IL-23 antihumanos cristalinos
CN104619334A (zh)	2012-08-09	2015-05-13	利兰斯坦福初级大学董事会	超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子
UA117466C2 (uk)	2012-12-13	2018-08-10	Мерк Шарп Енд Доме Корп.	СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
WO2014171721A1 (ko) *	2013-04-16	2014-10-23	가톨릭대학교 산학협력단	아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
KR101625112B1 (ko)	2013-04-16	2016-05-27	가톨릭대학교 산학협력단	아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
EP3049526B1 (en)	2013-09-24	2021-02-24	Medicenna Therapeutics, Inc.	Interleukin-4 receptor-binding fusion proteins and uses thereof
EP3708679A1 (en)	2014-07-24	2020-09-16	Boehringer Ingelheim International GmbH	Biomarkers useful in the treatment of il-23a related diseases
EA202193002A2 (ru)	2014-09-03	2022-03-31	Бёрингер Ингельхайм Интернациональ Гмбх	Соединение, нацеленное на ил-23a и фно-альфа, и его применение
JP6219875B2 (ja) *	2015-04-10	2017-10-25	株式会社スクウェア・エニックス	ネットワークゲームシステム、ゲーム装置及びプログラム
JP7382232B2 (ja)	2017-05-02	2023-11-16	メルク・シャープ・アンド・ドーム・エルエルシー	抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3694558B1 (en)	2017-10-10	2024-04-10	Medicenna Therapeutics Inc.	Il-4-fusion formulations for treatment of central nervous system (cns) tumors
WO2019239213A2 (en)	2018-06-01	2019-12-19	Medicenna Therapeutics Inc.	Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
US12590133B2 (en)	2018-06-01	2026-03-31	The Board Of Trustees Of The Leland Stanford Junior University	IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof
WO2020081408A1 (en)	2018-10-18	2020-04-23	Merck Sharp & Dohme Corp.	Formulations of anti-rsv antibodies and methods of use thereof
MX2021004928A (es)	2018-10-31	2021-06-08	Merck Sharp & Dohme Llc	Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
EP3876990A4 (en)	2018-11-07	2023-09-06	Merck Sharp & Dohme LLC	CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
IL283192B2 (en)	2018-11-20	2025-10-01	Janssen Biotech Inc	A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
JP7805788B2 (ja)	2019-05-23	2026-01-26	ヤンセンバイオテツク，インコーポレーテツド	Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
TW202535466A (zh)	2019-09-09	2025-09-16	德商百靈佳殷格翰國際股份有限公司	抗-il-23p19抗體調配物
IL298389A (en)	2020-05-21	2023-01-01	Janssen Biotech Inc	Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
CN114317430A (zh) *	2021-12-28	2022-04-12	河北银丰鼎诚生物技术有限公司	一种适用于脐血来源免疫细胞扩增的培养液

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69034249T2 (de) *	1989-12-22	2008-05-29	F. Hoffmann-La Roche Ag	Monoklonale Antikörper spezifisch für den zytotoxischen Lymphozyten-Reifefaktor
DE4315127A1 (de) *	1993-05-07	1994-11-10	Behringwerke Ag	Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
US5851523A (en) *	1994-03-24	1998-12-22	Ludwig Institute For Cancer Research.	Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5853721A (en)	1995-01-31	1998-12-29	Hoffmann-La Roche Inc.	Antibody to interleukin-12 receptor
GB9609932D0 (en) *	1996-05-13	1996-07-17	Hoffmann La Roche	Use of IL-12 and IFN alpha for the treatment of infectious diseases
EP0956301A2 (en) *	1996-10-18	1999-11-17	Valentis Inc.	Il-12 gene expression and delivery systems and uses
ZA986596B (en) *	1997-07-25	1999-02-08	Schering Corp	Mammalian cytokine related reagents
WO1999040195A1 (en) *	1998-02-06	1999-08-12	Schering Corporation	Mammalian receptor proteins; related reagents and methods

2000
- 2000-09-08 AU AU73608/00A patent/AU780163B2/en not_active Expired
- 2000-09-08 DE DE60038304.0T patent/DE60038304T3/de not_active Expired - Lifetime
- 2000-09-08 IL IL14830000A patent/IL148300A0/xx active IP Right Grant
- 2000-09-08 MX MXPA02002684A patent/MXPA02002684A/es active IP Right Grant
- 2000-09-08 KR KR1020027003089A patent/KR100894359B1/ko not_active Expired - Lifetime
- 2000-09-08 JP JP2001522273A patent/JP4505166B2/ja not_active Expired - Lifetime
- 2000-09-08 EP EP00961688.9A patent/EP1210434B2/en not_active Expired - Lifetime
- 2000-09-08 HK HK02105118.4A patent/HK1044170B/en not_active IP Right Cessation
- 2000-09-08 WO PCT/US2000/024686 patent/WO2001018051A2/en not_active Ceased
- 2000-09-08 CA CA2388562A patent/CA2388562C/en not_active Expired - Lifetime
- 2000-09-08 ES ES00961688.9T patent/ES2300276T5/es not_active Expired - Lifetime
- 2000-09-08 HU HU0301102A patent/HU230679B1/hu unknown
- 2000-09-08 AT AT00961688T patent/ATE389019T1/de not_active IP Right Cessation
- 2000-09-08 CN CNB008154007A patent/CN100529076C/zh not_active Expired - Lifetime
- 2000-09-11 AR ARP000104753A patent/AR035560A1/es unknown
2006
- 2006-08-28 JP JP2006231402A patent/JP2007045830A/ja not_active Withdrawn
2008
- 2008-10-31 AU AU2008240348A patent/AU2008240348B2/en not_active Expired
2009
- 2009-06-19 JP JP2009147075A patent/JP4969610B2/ja not_active Expired - Lifetime
2010
- 2010-04-21 JP JP2010098317A patent/JP2010233571A/ja not_active Withdrawn
2013
- 2013-03-01 JP JP2013040389A patent/JP2013128489A/ja active Pending
2014
- 2014-10-07 JP JP2014206652A patent/JP6140122B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP6140122B2 (ja)	2017-05-31
JP2003510038A (ja)	2003-03-18
HUP0301102A2 (hu)	2003-07-28
JP2010233571A (ja)	2010-10-21
HUP0301102A3 (en)	2005-11-28
EP1210434B1 (en)	2008-03-12
CN100529076C (zh)	2009-08-19
EP1210434B2 (en)	2016-12-14
JP2013128489A (ja)	2013-07-04
IL148300A0 (en)	2002-09-12
JP2015051005A (ja)	2015-03-19
ES2300276T5 (es)	2017-06-02
KR20020034185A (ko)	2002-05-08
JP2007045830A (ja)	2007-02-22
AU7360800A (en)	2001-04-10
KR100894359B1 (ko)	2009-04-22
AU2008240348B2 (en)	2012-07-12
DE60038304T2 (de)	2009-03-19
AR035560A1 (es)	2004-06-16
CN1387571A (zh)	2002-12-25
MXPA02002684A (es)	2002-07-30
HK1044170B (en)	2008-08-01
ES2300276T3 (es)	2008-06-16
JP4505166B2 (ja)	2010-07-21
JP4969610B2 (ja)	2012-07-04
DE60038304D1 (de)	2008-04-24
WO2001018051A3 (en)	2001-09-20
AU2008240348A1 (en)	2008-11-27
WO2001018051A2 (en)	2001-03-15
CA2388562C (en)	2014-07-22
AU780163B2 (en)	2005-03-03
ATE389019T1 (de)	2008-03-15
JP2009268467A (ja)	2009-11-19
CA2388562A1 (en)	2001-03-15
HK1044170A1 (en)	2002-10-11
EP1210434A2 (en)	2002-06-05
DE60038304T3 (de)	2017-04-06

Legal Events

Date

Code

Title

Description

2006-05-29

FH91

Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): BELICZAY LASZLO, S.B.G. & K. SZABADALMI UEGYVIVOEI IRODA, HU

Representative=s name: RATHONYI ZOLTAN, S.B.G. & K. SZABADALMI UEGYVI, HU

2006-05-29

FH92

Termination of representative

Representative=s name: BELICZAY LASZLO, S.B.G. & K. SZABADALMI UEGYVI, HU

2012-09-28

HC9A

Change of name, address

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER(S): SCHERING CORP., US

Publication	Publication Date	Title
HU230679B1 (en)	2017-08-28	Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
Radwanska et al.	2018	Salivarian trypanosomosis: a review of parasites involved, their global distribution and their interaction with the innate and adaptive mammalian host immune system
Heffelfinger	2018	Deer of the Southwest: a complete guide to the natural history, biology, and management of southwestern mule deer and white
HU230629B1 (hu)	2017-04-28	Emlős citokin: interleukin-B30 és rokon molekulák
UA121093C2 (uk)	2020-04-10	Конструкція, яка містить токсиген, що кодує пестицидний білок, і спосіб її застосування для знищення напівтвердокрилих шкідників
HUE026089T2 (hu)	2016-05-30	NGF elleni antitestek és eljárás alkalmazásukra
Bodmer	1995	The book of man: the Human Genome Project and the quest to discover our genetic heritage
UA126549C2 (uk)	2022-11-02	Композиція і спосіб для з'єднання позаклітинних доменів типу і та типу іі як гетерологічного химерного білка
DeVita et al.	2015	The death of cancer: after fifty years on the front lines of medicine, a pioneering oncologist reveals why the war on cancer is winnable--and how we can get there
UA114173C2 (uk)	2017-05-10	Пристрій та спосіб для проведення проточної цитометрії
UA126972C2 (uk)	2023-03-01	Аденовірус, озброєний біспецифічним рекрутером t-клітин (bite)
HU230334B1 (hu)	2016-02-29	Vírus közreműködésével történő, a citoszolba irányuló molekulabevitelre szolgáló fotokémiai internalizáció és eljárás
UA124293C2 (uk)	2021-08-25	Рослина, яка має біологічну активність гаплоїдного індуктора, і спосіб її застосування
UA121662C2 (uk)	2020-07-10	Химерний інсектицидний білок, інгібіторний відносно лускокрилих шкідників
UA129947C2 (uk)	2025-09-24	Спосіб застосування коагоніста gip/glp1 при діабеті
Donin et al.	2020	Taxonomical study of Trichomycterus (Siluriformes: Trichomycteridae) from the Ribeira de Iguape River basin reveals a new species recorded in the early 20th century
UA128365C2 (uk)	2024-06-26	Спосіб та набір для визначення статі пташиних ембріонів у невиведених яйцях
Wapner	2014	The Philadelphia chromosome: a genetic mystery, a lethal cancer, and the improbable invention of a lifesaving treatment
Enriquez et al.	2016	Evolving ourselves: redesigning the future of humanity--one gene at a time
HU228978B1 (en)	2013-07-29	Use of long pentraxin ptx3 for treating female infertility
O'Brien	2003	Tears of the cheetah: and other tales from the genetic frontier
Rittner et al.	2004	Encyclopedia of biology
UA127388C2 (uk)	2023-08-09	Регуляторний елемент рослини і спосіб його застосування
BG98079A (bg)	1994-06-30	Инсектицидно ефективни пептиди
Arney	2020	Rebel Cell: Cancer, Evolution, and the New Science of Life's Oldest Betrayal